This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.07.076v1 50/22/2156    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (30) Citing Articles via Google Scholar Google Scholar Articles by Hohnloser, S. H. Search for Related Content PubMed PubMed Citation Articles by Hohnloser, S. H.

CLINICAL RESEARCH: HEART RHYTHM DISORDER

Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy

An ACTIVE W Substudy

Stefan H. Hohnloser, MD, FACC^_*,_*, Dimitri Pajitnev, MD^_*, Janice Pogue, PhD, Jeff S. Healey, MD, Marc A. Pfeffer, MD, FACC, Salim Yusuf, MD, FACC, Stuart J. Connolly, MD, FACC for the ACTIVE W Investigators

^_* Department of Cardiology, Division of Electrophysiology, J. W. Goethe University, Frankfurt, Germany
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Brigham and Women’s Hospital, Boston, Massachusetts.

Manuscript received May 24, 2007; revised manuscript received July 10, 2007, accepted July 24, 2007.

^_* Reprint requests and correspondence: Dr. Stefan H. Hohnloser, J. W. Goethe University, Department of Cardiology, Division of Electrophysiology, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. (Email: Hohnloser{at}em.uni-frankfurt.de).

Objectives: Our goal was to determine the risk of stroke or non-cerebral embolism associated with paroxysmal compared with sustained atrial fibrillation (AF).

Background: The risk of stroke and non-cerebral embolism and the efficacy of oral anticoagulation (OAC) in paroxysmal AF as compared with sustained AF are not precisely known.

Methods: The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in 6,706 AF patients. The incidence of thromboembolic events and major bleeds were compared in patients with paroxysmal AF (n = 1,202) and persistent or permanent AF (n = 5,495).

Results: Patients with paroxysmal AF were younger, had a shorter AF history, more hypertension, and less valvular disease, heart failure, and diabetes mellitus than patients with sustained AF. At baseline, patients with paroxysmal AF had a CHADS₂ (cardiac failure, hypertension, age, diabetes, stroke [doubled]) risk score of 1.79 ± 1.03 compared with 2.04 ± 1.12 in patients with sustained AF (p < 0.00001). The annualized risk of stroke or non-central nervous system (CNS) systemic embolism was 2.0 in paroxysmal AF compared with 2.2 in sustained AF (relative risk 0.87, 95% confidence interval [CI] 0.59 to 1.30, p = 0.496). After adjusting for confounding baseline variables, the relative risk was 0.94 (95% CI 0.63 to 1.40, p = 0.755). The incidence of stroke and non-CNS embolism was lower for patients treated with OAC irrespective of type of AF. There were more bleedings of any type in patients receiving clopidogrel plus aspirin, irrespective of the type of AF.

Conclusions: Patients with paroxysmal AF treated with aspirin plus clopidogrel or OAC have a similar risk for thromboembolic events than patients with sustained AF. This risk can be significantly lowered with OAC. (The ACTIVE W trial; http://www.clinicaltrials.gov/ct/show/NCT00243178 [ClinicalTrials.gov] ; NCT00243178)

Abbreviations and Acronyms   AF = atrial fibrillation   CI = confidence interval   CNS = central nervous system   INR = international normalized ratio   OAC = oral anticoagulation   RR = relative risk

This article has been cited by other articles:

				J. S. Healey Device-detected atrial tachyarrhythmias: what do we know? Europace, February 1, 2012; 14(2): 157 - 158. [Full Text] [PDF]

				J. J. You, D. E. Singer, P. A. Howard, D. A. Lane, M. H. Eckman, M. C. Fang, E. M. Hylek, S. Schulman, A. S. Go, M. Hughes, et al. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e531S - e575S. [Abstract] [Full Text] [PDF]

				J. Oldgren, M. Alings, H. Darius, H.-C. Diener, J. Eikelboom, M. D. Ezekowitz, G. Kamensky, P. A. Reilly, S. Yang, S. Yusuf, et al. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial Ann Intern Med, November 15, 2011; 155(10): 660 - 667. [Abstract] [Full Text] [PDF]

				K. Wasmer and L. Eckardt Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines Europace, October 1, 2011; 13(10): 1368 - 1374. [Abstract] [Full Text] [PDF]

				M. Endres, P. U. Heuschmann, U. Laufs, and A. M. Hakim Primary prevention of stroke: blood pressure, lipids, and heart failure Eur. Heart J., March 1, 2011; 32(5): 545 - 552. [Abstract] [Full Text] [PDF]

				L. B. Goldstein, C. D. Bushnell, R. J. Adams, L. J. Appel, L. T. Braun, S. Chaturvedi, M. A. Creager, A. Culebras, R. H. Eckel, R. G. Hart, et al. Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke, February 1, 2011; 42(2): 517 - 584. [Abstract] [Full Text] [PDF]

				R. Stahrenberg, M. Weber-Kruger, J. Seegers, F. Edelmann, R. Lahno, B. Haase, M. Mende, J. Wohlfahrt, P. Kermer, D. Vollmann, et al. Enhanced Detection of Paroxysmal Atrial Fibrillation by Early and Prolonged Continuous Holter Monitoring in Patients With Cerebral Ischemia Presenting in Sinus Rhythm Stroke, December 1, 2010; 41(12): 2884 - 2888. [Abstract] [Full Text] [PDF]

				N. Toh, H. Kanzaki, S. Nakatani, T. Ohara, J. Kim, K. F. Kusano, K. Hashimura, T. Ohe, H. Ito, and M. Kitakaze Left Atrial Volume Combined With Atrial Pump Function Identifies Hypertensive Patients With a History of Paroxysmal Atrial Fibrillation Hypertension, May 1, 2010; 55(5): 1150 - 1156. [Abstract] [Full Text] [PDF]

				L. Friberg, N. Hammar, and M. Rosenqvist Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation Eur. Heart J., April 2, 2010; 31(8): 967 - 975. [Abstract] [Full Text] [PDF]

				S. A. Lubitz, A. B. Rosen, P. T. Ellinor, and E. J. Benjamin Stroke risk in AF: do AF patterns matter? Eur. Heart J., April 2, 2010; 31(8): 908 - 910. [Full Text] [PDF]

				T. Watson, A. Arya, N. Sulke, and G. Y. H. Lip Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation Chest, April 1, 2010; 137(4): 869 - 876. [Abstract] [Full Text] [PDF]

				P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF' Eur. Heart J., December 2, 2009; 30(24): 2969 - 2980. [Abstract] [Full Text] [PDF]

				L.-P. Kan, K.-M. Chu, and G.-M. Lin Letter by Kan et al Regarding Article, "Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial" Circulation, November 17, 2009; 120(20): e164 - e164. [Full Text] [PDF]

				T. V. Glotzer, E. G. Daoud, D. G. Wyse, D. E. Singer, M. D. Ezekowitz, C. Hilker, C. Miller, D. Qi, and P. D. Ziegler The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 474 - 480. [Abstract] [Full Text] [PDF]

				L. Suissa, D. Bertora, S. Lachaud, and M. H. Mahagne Score for the Targeting of Atrial Fibrillation (STAF): A New Approach to the Detection of Atrial Fibrillation in the Secondary Prevention of Ischemic Stroke Stroke, August 1, 2009; 40(8): 2866 - 2868. [Abstract] [Full Text] [PDF]

				P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace, July 1, 2009; 11(7): 860 - 885. [Full Text] [PDF]

				R. G. Hart and L. A. Pearce Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation Stroke, July 1, 2009; 40(7): 2607 - 2610. [Full Text] [PDF]

				R. Nieuwlaat and S. J Connolly Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes Heart, January 15, 2009; 95(2): 95 - 97. [Full Text] [PDF]

				A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin Prevention of stroke in patients with atrial fibrillation: current strategies and future directions Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H4 - H10. [Abstract] [Full Text] [PDF]

				M. Stramba-Badiale Atrial fibrillation subtypes, risk of stroke, and antithrombotic therapy Eur. Heart J., April 1, 2008; 29(7): 840 - 842. [Full Text] [PDF]